Shanghai Haohai reports 7% revenue decline amid profit drop

Shanghai Haohai Biological Technology reported revenue of RMB1.29 billion for the six months ended June 30, down 7.48% from RMB1.40 billion in 2024.

Profit attributable to ordinary equity holders fell 10.29% to RMB211.07 million, compared to RMB235.28 million in 2024. Basic earnings per share dropped to RMB0.91 from RMB1.01.

R&D expenses decreased 21.53% to RMB98.40 million, representing 7.61% of revenue. The board declared an interim dividend of RMB0.40 per share, unchanged from the previous year.